NewGenIvf Group Ltd當前公司基本面數據相對穩定,增長潛力較大。當前估值低估,在醫療服務供應商行業排名74/78位。機構持股佔比低,近一個月多位分析師給出公司評級為。最高目標價75.00。中期看,股價處於下降通道。近一個月,市場表現非常差,基本面和技術面綜合得分也較低。目前股價在壓力位和支撐位之間,可以做區間波段操作。
NewGenIvf Group Ltd評分
相關信息
行業排名
74 / 78
全市場排名
521 / 4562
所屬行業
醫療服務供應商
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
0
分析師
--
評級
75.000
目標均價
+5036.99%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
NewGenIvf Group Ltd亮點
亮點風險
NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
公司代碼NIVF
公司NewGenIvf Group Ltd
CEOWing Fung (Siu)
網址https://newgenivf.com/
常見問題
NewGenIvf Group Ltd(NIVF)的當前股價是多少?
NewGenIvf Group Ltd(NIVF)的當前股價是 0.797。
NewGenIvf Group Ltd 的股票代碼是什麼?
NewGenIvf Group Ltd的股票代碼是NIVF。
NewGenIvf Group Ltd股票的52週最高點是多少?
NewGenIvf Group Ltd股票的52週最高點是2450.000。
NewGenIvf Group Ltd股票的52週最低點是多少?
NewGenIvf Group Ltd股票的52週最低點是0.781。
NewGenIvf Group Ltd的市值是多少?
NewGenIvf Group Ltd的市值是343.36K。
NewGenIvf Group Ltd的淨利潤是多少?
NewGenIvf Group Ltd的淨利潤為-524.64K。
現在NewGenIvf Group Ltd(NIVF)的股票是買入、持有還是賣出?
根據分析師評級,NewGenIvf Group Ltd(NIVF)的總體評級為--,目標價格為75.000。
NewGenIvf Group Ltd(NIVF)股票的每股收益(EPS TTM)是多少
NewGenIvf Group Ltd(NIVF)股票的每股收益(EPS TTM)是576.582。